Raymond Schuch

Raymond Schuch

Auto-generated profile, based on publicly available information

Raymond Schuch

ContraFect Corporation, Yonkers, New York, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RSRaymond Schuch
Raymond Schuch
BKBabar K. Khan
Babar K. Khan
ARAssaf Raz
Assaf Raz
JRJimmy A. Rotolo
Jimmy A. Rotolo
MWMichael Wittekind
Michael Wittekind
Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to targetStaphylococcus aureusbiofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95S. aureusstrains to obtain a 90% MBEC (MBEC90) value of ≤0.25 μg/ml for CF-301. Mature biofilms of coagulase-negative staphylococci,Streptococcus pyogenes, andStreptococcus agalactiaewere also sensitive to disruption, with MBEC90values ranging from 0.25 to 8 μg/ml. The potency of CF-301 was demonstrated againstS. aureusbiofilms formed on polystyrene, glass, surgical mesh, and catheters. In catheters, CF-301 removed all biofilm within 1 h and killed all released bacteria by 6 h. Mixed-species biofilms, formed byS. aureusandStaphylococcus epidermidison several surfaces, were removed by CF-301, as wereS. aureusbiofilms either enriched for small-colony variants (SCVs) or grown in human synovial fluid. The antibacterial activity of CF-301 was further demonstrated againstS. aureuspersister cells in exponential-phase and stationary-phase populations. Finally, the antibiofilm activity of CF-301 was greatly improved in combinations with the cell wall hydrolase lysostaphin when tested against a range ofS. aureusstrains. In all, the data show that CF-301 is highly effective at disrupting biofilms and killing biofilm bacteria, and, as such, it may be an efficient new agent for treating staphylococcal infections with a biofilm component.

1 July 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VFVance G Fowler
Vance G Fowler
ADAnita F. Das
Anita F. Das
JLJoy Lipka-Diamond
Joy Lipka-Diamond
RSRaymond Schuch
Raymond Schuch
RPRoger Pomerantz
Roger Pomerantz
CCCara Cassino
Cara Cassino
BACKGROUND. Novel therapeutic approaches are critically needed for Staphylococcus aureus bloodstream infections (BSIs), particularly for methicillin-resistant S. aureus (MRSA). Exebacase, a first-in-class antistaphylococcal lysin, is a direct lytic agent that is rapidly bacteriolytic, eradicates biofilms, and synergizes with antibiotics. METHODS. In this superiority-design study, we randomly assigned 121 patients with S. aureus BSI/endocarditis to receive a single dose of exebacase or placebo. All patients received standard-of-care antibiotics. The primary efficacy endpoint was clinical outcome (responder rate) on day 14. RESULTS. Clinical responder rates on day 14 were 70.4% and 60.0% in the exebacase + antibiotics and antibiotics-alone groups, respectively (difference = 10.4, 90% CI [–6.3, 27.2], P = 0.31), and were 42.8 percentage points higher in the prespecified exploratory MRSA subgroup (74.1% vs. 31.3%, difference = 42.8, 90% CI [14.3, 71.4], ad hoc P = 0.01). Rates of adverse events (AEs) were similar in both groups. No AEs of hypersensitivity to exebacase were reported. Thirty-day all-cause mortality rates were 9.7% and 12.8% in the exebacase + antibiotics and antibiotics-alone groups, respectively, with a notable difference in MRSA patients (3.7% vs. 25.0%, difference = –21.3, 90% CI [–45.1, 2.5], ad hoc P = 0.06). Among MRSA patients in the United States, median length of stay was 4 days shorter and 30-day hospital readmission rates were 48% lower in the exebacase-treated group compared with antibiotics alone. CONCLUSION. This study establishes proof of concept for exebacase and direct lytic agents as potential therapeutics and supports conduct of a confirmatory study focused on exebacase to treat MRSA BSIs. TRIAL REGISTRATION. Clinicaltrials.gov NCT03163446. FUNDING. ContraFect Corporation.

1 June 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RHRyan Heselpoth
Ryan Heselpoth
CEChad W. Euler
Chad W. Euler
RSRaymond Schuch
Raymond Schuch
VFVincent A. Fischetti
Vincent A. Fischetti
The prevalence of multidrug-resistant Pseudomonas aeruginosa has stimulated development of alternative therapeutics. Bacteriophage peptidoglycan hydrolases, termed lysins, represent an emerging antimicrobial option for targeting Gram-positive bacteria.

1 April 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CIChiara Indiani
Chiara Indiani
KSKaren Sauve
Karen Sauve
ARAssaf Raz
Assaf Raz
WAWessam Abdelhady
Wessam Abdelhady
YXYan Q. Xiong
Yan Q. Xiong
RSRaymond Schuch
Raymond Schuch
Bacteriophage-derived lysins are cell wall hydrolytic enzymes which represent a potential new class of antibacterial therapeutics in development to address burgeoning antimicrobial resistance. CF-301, the lead compound in this class, is in clinical development as an adjunctive treatment to potentially improve clinical cure rates of Staphylococcus aureus bacteremia and infective endocarditis (IE) when used in addition to antibiotics. In order to profile CF-3019s activity in a clinically relevant milieu, we assessed its in vitro activity in human blood vs. in a conventional testing medium (cation-adjusted Mueller Hinton Broth [caMHB]). CF-301 exhibited substantially greater potency (32-≥100-fold) in human blood vs. caMHB in three standard microbiologic testing formats (e.g. broth dilution MICs, checkerboard synergy and time-kill assays). We demonstrated that CF-301 acted synergistically with two key human blood factors, human serum lysozyme (HuLYZ) and albumin (HSA), which normally have no nascent antistaphylococcal activity, against a prototypic MRSA strain (MW2). Similar in vitro enhancement of CF-301 activity was also observed in rabbit, horse and dog (but not rat or mouse) blood. Two well-established MRSA IE models in rabbit and rat were used to validate these findings in vivo by demonstrating comparable synergistic efficacy with standard-of-care anti-MRSA antibiotics, at > 100-fold lower lysin doses in the rabbit vs the rat model. The unique properties of CF-301 which enable bactericidal potentiation of antimicrobial activity via activation of ‘latent’ host factors in human blood may have important therapeutic implications for the durable improvements in clinical outcomes of serious, antibiotic-resistant staphylococcal infections.

10 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRaymond Schuch
Raymond Schuch
APAdam J. Pelzek
Adam J. Pelzek
ARAssaf Raz
Assaf Raz
CEChad W. Euler
Chad W. Euler
PRPatricia A. Ryan
Patricia A. Ryan
VFVincent A. Fischetti
Vincent A. Fischetti
We identified an essential cell wall biosynthetic enzyme in Bacillus anthracis and an inhibitor thereof to which the organism did not spontaneously evolve measurable resistance. This work is based on the exquisite binding specificity of bacteriophage-encoded cell wall-hydrolytic lysins, which have evolved to recognize critical receptors within the bacterial cell wall. Focusing on the B. anthracis-specific PlyG lysin, we first identified its unique cell wall receptor and cognate biosynthetic pathway. Within this pathway, one biosynthetic enzyme, 2-epimerase, was required for both PlyG receptor expression and bacterial growth. The 2-epimerase was used to design a small-molecule inhibitor, epimerox. Epimerox prevented growth of several Gram-positive pathogens and rescued mice challenged with lethal doses of B. anthracis. Importantly, resistance to epimerox was not detected (<10−11 frequency) in B. anthracis and S. aureus. These results describe the use of phage lysins to identify promising lead molecules with reduced resistance potential for antimicrobial development.

1 October 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AWAubrey Watson
Aubrey Watson
JOJun Taek Oh
Jun Taek Oh
KSKaren Sauve
Karen Sauve
PBPatricia A. Bradford
Patricia A. Bradford
CCCara Cassino
Cara Cassino
RSRaymond Schuch
Raymond Schuch
Exebacase, a recombinantly produced lysin (cell wall hydrolase), and comparator antibiotics were tested by the broth microdilution method against strain sets of Staphylococcus and Streptococcus spp., which are the most common causes of infective endocarditis in humans. Exebacase was active against all Staphylococcus spp. tested, including S. aureus and coagulase-negative staphylococci (MIC 50/90 , 0.5/1 μg/ml). Activity against Streptococcus spp.